Published 2 days ago • loading... • Updated 2 days agoShow Less IconWells Fargo & Company Begins Coverage on Supernus Pharmaceuticals (NASDAQ:SUPN) Summary by MarketBeatWells Fargo & Company started coverage on shares of Supernus Pharmaceuticals in a research note on Friday. They issued an "overweight" rating and a $54.00 price objective on the stock.Share menu1 Articles1 ArticlesAllLeftCenter1RightSearch IconSort IconMarketBeatCenterFactualityOwnershipWells Fargo & Company Begins Coverage on Supernus Pharmaceuticals (NASDAQ:SUPN)Wells Fargo & Company started coverage on shares of Supernus Pharmaceuticals in a research note on Friday. They issued an "overweight" rating and a $54.00 price objective on the stock.2 days ago·Sioux Falls, United StatesRead Full ArticleThink freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribeBlindspot Title And LogoStories disproportionately reported by the Left or the RightSee More BlindspotsCoverage DetailsTotal News Sources1Leaning Left0Leaning Right0Center1Last Updated2 days agoBias Distribution100% CenterBias Distribution Too Big Arrow IconToo Big Arrow IconCaret Up Icon100% of the sources are Center100% CenterC 100%Factuality Info IconTo view factuality data please Upgrade to PremiumOwnership Info IconTo view ownership data please Upgrade to VantageMarketBeat broke the news in Sioux Falls, United States 2 days ago on Friday, November 20, 2026.Too Big Arrow IconCaret Down IconSources are mostly out of (0)Similar News TopicsRockville, Maryland Plus IconShow AllBlindspot Title And LogoStories disproportionately reported by the Left or the RightSee More BlindspotsSimilar News TopicsRockville, Maryland Plus IconShow All